RPRD Diagnostics, LLC

Wauwatosa, WI · Medtech · Private

CYP2D6 pharmacogenetic diagnostic test using CRISPR-Cas9 sequencing to accurately characterize genetic variants for drug metabolism prediction

rprdx.com →
Grants
$168K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
$521K
1 award · Health and Human S
#381 of 4531 in medtech
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Innovative approach to full length sequence analysis of CYP2D6 gene.$168,087
Federal contractDepartment of Health and Human Services · Pharmacogenetic Allele Frequencies Study$520,661
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
378Oxford Performance Materials, Inc.$547K$46M
379PROMPT DIAGNOSTICS, INC.$543K—
380ANTIMICROBIAL MATERIALS INC$538K—
381RPRD Diagnostics, LLC$521K—
382BARRETT TECHNOLOGY, LLC$505K—
383KLAR SCIENTIFIC, INC.$492K$120K
384ENCISION INC$485K$3.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 6
  • Methods And Systems For Analyzing Complex Genomic Regionsapplication
  • Methods And Systems For Analyzing Complex Genomic Regionsapplication
  • Methods And Systems For Analyzing Complex Genomic Regionsapplication
  • Methods And Systems For Analyzing Complex Genomic Regionsapplication
  • Methods And Systems For Analyzing Complex Genomic Regionsapplication
  • Methods For Genotyping Cytochrome P450 2D6 By Long-range Sequencingapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.